Audiological findings in a Phase I protocol investigating the effect of WR 2721, high-dose cisplatin and radiation therapy in patients with locally advanced cervical carcinoma

John S. Rubin, Jonathan J. Beitler, Alla Rozenblit, Scott Wadler, Hilda Haynes, Frances McGill, Gary Goldberg, Carolyn Runowicz

Research output: Contribution to journalArticle

24 Scopus citations


WR 2721 (ethiofos) protects against the toxic effects of the heavy metal compound cisplatin. which is used in the treatment of solid tumours. In a Phase I protocol designed to determine the maximum dose of WR 2721 which could be tolerated when administered in combination with cisplatin and radiation therapy to patients with cervical carcinoma, 11 patients were evaluated by audiologic testing before and after cisplatin WR 2721 administration in an attempt to identify the degree of ototoxicity. Forty-five per cent were noted to have significant hearing threshold changes, predominantly in the high frequencies. There were no significant changes in the speech frequencies in this series. This contrasts with the greater degrees of ototoxicity observed in controls treated in the same way who received cisplatin without WR 2721 protection.

Original languageEnglish (US)
Pages (from-to)744-747
Number of pages4
JournalThe Journal of Laryngology & Otology
Issue number8
Publication statusPublished - Aug 1995



  • Audiometry
  • Cisplatin
  • Hearing loss
  • Ototoxicity
  • sensorineural

ASJC Scopus subject areas

  • Otorhinolaryngology

Cite this